Back to Alerts
Healthcare•9d ago

RARE Maintained by Canaccord Genuity -- Price Target Lowered to $37.00

RARE Maintained by Canaccord Genuity -- Price Target Lowered to $37.00

Ultragenyx Pharmaceutical (RARE) Analyst Rating Update On September 3, 2026, Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Ultragenyx Pha

GuruFocus
Article
News
GuruFocus News
RARE
Source: gurufocus.com

Sponsored

Sponsored

Master the Millennial Market mindset

Learn advanced portfolio strategies for 2024

Market Sectors

Blogs12

Markets8

Subscribers15

Related Alerts

3 Reports
RARE Maintained by Wedbush -- Price Target Lowered to $23.00Healthcare
Source: gurufocus.com9d ago

RARE Maintained by Wedbush -- Price Target Lowered to $23.00

Ultragenyx Pharmaceutical (RARE) Analyst Rating Update On October 5, 2023, Wedbush maintained a Neutral rating on Ultragenyx Pharmaceutical Inc (RARE). The f

Verified Marketplace IntelligenceREAD REPORT
RARE Downgraded by Baird -- Price Target Lowered to $16.00Healthcare
Source: gurufocus.com9d ago

RARE Downgraded by Baird -- Price Target Lowered to $16.00

Ultragenyx Pharmaceutical Inc (RARE) Analyst Rating Update On October 03, 2023, Ultragenyx Pharmaceutical (RARE) was downgraded by Baird analyst Joel Beatty

Verified Marketplace IntelligenceREAD REPORT
RARE Maintained by Cantor Fitzgerald -- Price Target Lowered to $33Healthcare
Source: gurufocus.com9d ago

RARE Maintained by Cantor Fitzgerald -- Price Target Lowered to $33

On October 03, 2023, the analyst rating for Ultragenyx Pharmaceutical Inc (RARE) was maintained as Overweight by Cantor Fitzgerald. The price target has been si

Verified Marketplace IntelligenceREAD REPORT